Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China Bevacizumab biosimilar CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar Ranibizumab biosimilar and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA AbbVie, Inc. Pfizer, Inc. Bioeq AG Innovent Biologics (Suzhou) Co., Ltd. and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.